A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy

Molecular Therapy

Volumn 9, Issue 6, 2004, Pages 804-817

  Chia, Marie C ^a,b   Shi, Wei ^a   Li, Jian Hua ^a   Sanchez, Otto ^a,c   Strathdee, Craig A ^d   Huang, Dolly ^e   Busson, Pierre ^f   Klamut, Henry J ^a,b   Liu, Fei Fei ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d AMGEN INC   (United States)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Epstein Barr virus; Gene therapy; Nasopharyngeal cancer; Oncolytic virotherapy

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; E1A PROTEIN; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; FIBROBLAST; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER DYSFUNCTION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; CARCINOMA; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; DNA REPLICATION; GENE THERAPY; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY; LIVER; MICE; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; SPLEEN; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 3042771506     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.03.016     Document Type: Article

References (48)

1. Chow E. et al. Radiotherapy alone in patients with advanced nasopharyngeal cancer: comparison with an intergroup study - is combined modality treatment really necessary? Radiother. Oncol. 63 2002 269-274
2. Hildesheim A. Levine P.H. Etiology of nasopharyngeal carcinoma - a review Epidemiol. Rev. 15 1993 466-485
3. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC Semin. Cancer Biol. 12 2002 431-441
4. Tsao S.W. Tramoutanis G. Dawson C.W. Lo A.K.F. Huang D.P. The significance of LMP1 expression in nasopharyngeal carcinoma Semin. Cancer Biol. 12 2002 473-487
5. Leight E.R. Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus Rev. Med. Virol. 10 2000 83-100
6. Bochkarev A. Barwell J.A. Pfuetzner R.A. Bochkareva E. Frappier L. Edwards A.M. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA Cell 84 1996 791-800
7. Langle-Rouault F. et al. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids J. Virol. 72 1998 6181-6185
8. Kaneda Y. Saeki Y. Nakabayashi M. Zhou W.Z. Kaneda M.W. Morishita R. Enhancement of transgene expression by cotransfection of oriP plasmid with EBNA-1 expression vector Hum. Gene Ther. 11 2000 471-479
9. Li J.H. et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma Cancer Res. 62 2002 171-178
10. Goldsmith K.T. Dion L.D. Curiel D.T. Garver R.I. Trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus Virology 248 1998 406-419
11. Kirn D. Martuza R.L. Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat. Med. 7 2001 783-789
12. Li J.H. Li P. Klamut H. Liu F.F. Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines Clin. Cancer Res. 3 1997 507-514
13. Li J.H. Lax S.A. Kim J. Klamut H. Liu F.F. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma Int. J. Radiat. Oncol. Biol. Phys. 43 1999 607-616
14. Lax S.A. Chia M.C. Busson P. Klamut H.J. Liu F.F. Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts Radiother. Oncol. 61 2001 309-312
15. McGrory W.J. Bautista D.S. Graham F.L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5 Virology 163 1988 614-617
16. Church G.M. Gilbert W. Genomic sequencing Proc. Natl. Acad. Sci. USA 81 1984 1991-1995
17. Livak K.J. Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T) (-ΔΔC) method Methods 25 2001 402-408
18. Li J.H. et al. Efficacy of ionizing radiation combined with adenoviral p53 therapy in EBV-positive nasopharyngeal carcinoma Int. J. Cancer 87 2000 606-610
19. Vile R. Ando D. Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider Cancer Gene Ther. 9 2002 1062-1067
20. Green M. Daesch G.E. Biochemical studies on adenovirus multiplication. 2. Kinetics of nucleic acid and protein synthesis in suspension cultures Virology 13 1961 169
21. Kurihara T. Brough D.E. Kovesdi I. Kufe D.W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen J. Clin. Invest. 106 2000 763-771
22. Ganly I. Kim Y.T. Hann B. Balmain A. Brown R. Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis Gene Ther. 8 2001 369-375
23. Bischoff J. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373-376
24. Rogulski K.R. et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy Cancer Res. 60 2000 1193-1196
25. Goodrum F.D. Ornelles D.A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection J. Virol. 72 1998 9479-9490
26. Rothmann T. Hengstermann A. Whitaker N.J. Scheffner M. zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells J. Virol. 72 1998 9470-9478
27. Barker D.D. Berk A.J. Adenovirus proteins from both E1b reading frames are required for transformation of rodent cells by viral infection and DNA transfection Virology 156 1987 107-121
28. Bridge E. Ketner G. Interaction of adenoviral E4 and E1b products in late gene expression Virology 174 1990 345-353
29. Debbas M. White E. Wild-type p53 mediates apoptosis by E1a, which is inhibited by E1b Genes Dev. 7 1993 546-554
30. Rao L. Debbas M. Sabbatini P. Hockenbery D. Korsmeyer S. White E. The adenovirus E1a proteins induce apoptosis, which is inhibited by the E1b 19-kDa and Bcl-2 proteins Proc. Natl. Acad. Sci. USA 89 1992 7742-7746
31. Yew P.R. Liu X. Berk A.J. Adenovirus E1b oncoprotein tethers a transcriptional repression domain to p53 Genes Dev. 8 1994 190-202
32. Henderson S. et al. Induction of Bcl-2 expression by Epstein-Barr-virus latent membrane protein-1 protects infected B-cells from programmed cell-death Cell 65 1991 1107-1115
33. Lamfers M.L.M. et al. Potential of the conditionally replicative adenovirus Ad5-Delta 24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy Cancer Res. 62 2002 5736-5742
34. Chmura S.J. Advani S.J. Kufe D.W. Weichselbaum R.R. Strategies for enhancing viral-based gene therapy using ionizing radiation Radiat. Oncol. Invest. 7 1999 261-269
35. Shao R.P. et al. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of I kappa B kinases and nuclear factor kappa B activities J. Biol. Chem. 274 1999 21495-21498
36. Chang J.Y. Xia W. Shao R. Gupta-Burt S. Saxena V.A. Hung M.C. Radiation sensitization of HER-2/NEU overexpressing head and neck cancer by E1A gene therapy Radiology 221 2001 178-179
37. Shao R. et al. Inhibition of nuclear factor-kappa B activity is involved in E1A-mediated sensitization of radiation-induced apoptosis J. Biol. Chem. 272 1997 32739-32742
38. Shao R.P. et al. E1A inhibition of radiation-induced NF-kappa B activity through suppression of IKK activity and I kappa B degradation, independent of Akt activation Cancer Res. 61 2001 7413-7416
39. Hiscott J. Kwon H. Genin P. Hostile takeovers: viral appropriation of the NF-kappa B pathway J. Clin. Invest. 107 2001 143-151
40. Paielli D.L. et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse Mol. Ther. 3 2000 263-274
41. Nelson J.E. Kay M.A. Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication J. Virol. 71 1997 8902-8907
42. Harrison D. Sauthoff H. Heitner S. Jagirdar J. Rom W.N. Hay J.G. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19-kD gene increases the viral oncolytic effect Hum. Gene Ther. 12 2001 1323-1332
43. Jain R.K. Delivery of molecular and cellular medicine to solid tumors Adv. Drug Delivery Rev. 26 1997 71-90
44. Kopfmaier P. Kestenbach U. The interaction between host-supplied connective-tissue and xenografted human tumor-cells Anticancer Res. 10 1990 161-171
45. Durand R.E. Olive P.L. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids Methods in Cell Biology Vol. 64 2001 211-233 Academic Press San Diego
46. Wildner O. Morris J.C. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: dissemination, persistence, shedding, and pathogenicity Hum. Gene Ther. 13 2002 101-112
47. Ganly I. et al. A phase I study of Onyx-015, an ELB-attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin. Cancer Res. 6 2000 798-806
48. Freytag S.O. et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res. 62 2002 4968-4976